Other · developed by Novo Nordisk
NNC0487-0111 is a subcutaneously injected agent given via pre-filled pen-injectors to the thigh, abdomen or upper arm. It is being studied in obesity, overweight and obstructive sleep apnoea.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07533175 | Phase 3 | Diabetes Mellitus | Active not recruiting | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ObesityObstructive Sleep ApnoeaOverweight
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →